Please assess the completion status of the following clinical trial:

Trial Title: Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 to 65 (inclusive) years old at Visit 1 (Screening)~2. Male, or if female and met all of the following criteria:~   1. Not breastfeeding~  2. Negative pregnancy test result at Visit 1 (Screening) (not applicable to hysterectomized females)~  3. Surgically sterile, postmenopausal, or if of childbearing potential, practiced and was willing to continue to practice appropriate birth control during the entire duration of the study~3. Body mass index (BMI) of 25.0 to 35.0 kg/m² (inclusive) at Visit 1 (Screening)~4. Had a physical examination with no clinically significant abnormalities as judged by the investigator~5. Had normal renal function with an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation~6. Ability to understand and willingness to adhere to protocol requirements~Exclusion Criteria:~1. Had a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:~   1. Hepatic disease~  2. Gastrointestinal disease~  3. Endocrine disorder (including diabetes and impaired glucose tolerance)~  4. Cardiovascular disease~  5. Central nervous system diseases~  6. Psychiatric or neurological disorders~  7. Organ transplantation~  8. Chronic or acute infection~  9. Orthostatic hypotension, fainting spells or blackouts~  10. Allergy or hypersensitivity~2. Had any chronic disease requiring medication that was adjusted in the past 90 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)~3. Had major surgery of any kind within 6 months of Visit 1 (Screening)~4. Had a history of \>6 kg weight change within 3 months of Visit 1 (Screening)~5. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities judged by the investigator to be clinically significant at Visit 1 (Screening)~6. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study~7. Had any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening)~8. Currently abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures~9. Smoked more than 10 cigarettes per day, 3 cigars per day, 3 pipes per day, used more than 1 can of smokeless tobacco per week, or used a combination of tobacco products that approximate nicotine doses equivalent to 10 cigarettes per day~10. Had donated blood within 3 months of the date of the first dose of randomized study medication, or was planning to donate blood during the study~11. Had received any investigational drug within 2 months (or five half-lives of the investigational drug, whichever was greater) of the date of the first dose of randomized study medication~12. Had known allergies or hypersensitivity to any component of study treatment~13. Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 500 mg Met DR BID (Type: EXPERIMENTAL): Two doses of 500 mg metformin delayed-release
- 1000 mg Met DR BID (Type: EXPERIMENTAL): Two doses of 1000 mg metformin delayed-release
- 1000 mg Met IR BID (Type: ACTIVE_COMPARATOR): Two doses of 1000 mg metformin immediate-release
- 2000 mg Met XR QD (Type: ACTIVE_COMPARATOR): Single dose of 2000 mg metformin extended-release

Based on this trial design, predict the completion outcome and termination type (if applicable).